[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345403-105":59,"doc-detail-345403-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","everolimus-destabilizes-thymidylate-synthase-via-suppressing-its-o-glcnacylation-and-sensitizes-her2-negative-breast-cancer-to-fluorouracil","Everolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil","","Everolimus enhances the effectiveness of 5-fluorouracil (5-FU) and capecitabine in HER2-negative breast cancer, addressing limited response to fluoropyrimidines. The study targets thymidylate synthase (TYMS), linking drug sensitivity to TYMS as a predictive biomarker and mechanistic driver. Everolimus downregulates TYMS through proteasomal degradation via an ubiquitination-independent route by reducing OGT expression and TYMS O-GlcNAcylation, destabilizing TYMS homodimers. OGT overexpression reverses TYMS degradation, and patient specimens show decreased TYMS and OGT after everolimus-containing treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/everolimus-destabilizes-thymidylate-synthase-via-suppressing-its-o-glcnacylation-and-sensitizes-her2-negative-breast-cancer-to-fluorouracil/345403/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/everolimus-destabilizes-thymidylate-synthase-via-suppressing-its-o-glcnacylation-and-sensitizes-her2-negative-breast-cancer-to-fluorouracil/345403.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does everolimus sensitize HER2-negative breast cancer to 5-FU or capecitabine?","Question",{"text":112,"@type":113},"Everolimus significantly enhances 5-FU efficacy and suppresses TYMS by promoting its proteasomal degradation, thereby sensitizing HER2-negative breast cancer to fluoropyrimidines.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role do OGT and O-GlcNAcylation play in the proposed mechanism?",{"text":117,"@type":113},"Everolimus downregulates OGT, which reduces O-GlcNAcylation of TYMS. This promotes TYMS dissociation into monomers and ubiquitin-independent degradation.",{"name":119,"@type":110,"acceptedAnswer":120},"Does restoring OGT affect TYMS degradation?",{"text":121,"@type":113},"Yes. Overexpression of OGT reverses TYMS degradation caused by everolimus, supporting OGT-dependent control of TYMS stability.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345403,1790814609,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nEverolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to ﬂuorouracil  \nXiao-Ting Jiang 1,2,3, Huipei Gan 1,2,3, Shaoyi Wang 1,2,3, Linghan Wang 1,2, Zijie Cai1,2, Lok Lam Wong 1,2, Jingru Wang 1,2, Mengdi Zhu1,2, Nianqiu Liu1,2, Wang Yang 1,2, Yujie Liu 1,2, Liang Jin1,2, Yudong Li1,2, Shunying Li 1,2, Qianfeng Shi1,2, Jinna Lin 1,2, Keyang Qian 1,2, Qi Wang1,2, Xin Yang 1,2, Zhuangqiu Yang 1,2, Yingyan Chen 1,2, Yinxia Wu 1,2 and Qiang Liu 1,2 ✉  \n© The Author(s) 2026  \n\n|  | 5-Fluorouracil (5-FU) and its prodrugs are widely used drugs for chemotherapy in various cancers. However, their effectiveness in breast cancer is limited. mTORC1 pathway, as a known mediator of therapy resistance in breast cancer, presents a compelling target for combination approaches. This study investigated the mTORC1 inhibitor everolimus as a sensitizer to 5-FU and capecitabine in breast cancer, exploring thymidylate synthase (the direct target of 5-FU) as a predictive biomarker and targeted mechanism. Our results demonstrate that everolimus signiﬁcantly enhances 5-FU efﬁcacy in HER2-negative breast cancer in vivo and in vitro. Mechanistically, everolimus downregulates thymidylate synthase (TYMS) by inducing its proteasomal degradation through a ubiquitination-independent way involving downregulation of O-GlcNAc transferase (OGT) and a reduced O-GlcNAcylation of TYMS, which destabilizes TYMS homodimer. Overexpression of OGT reversed TYMS degradation. Importantly, this combination strategy was effective in refractory breast cancer patients, and decreased levels of TYMS and OGT were observed in breast cancer patient specimens collected before and after everolimus-containing treatment. In conclusion, our study reveals that everolimus sensitizes breast cancer to ﬂuoropyrimidines by destabilizing TYMS through modulation of its O-GlcNAcylation. These ﬁndings support a |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| promising combination strategy to improve the therapeutic efﬁcacy of 5-FU and capecitabine in breast cancer. |  |  |\n|  | Cell Death and Disease (2026)17:456; [https://doi.org/10.1038/s41419-026-08715-z](https://doi.org/10.1038/s41419-026-08715-z) |  |\n|  |  |  |\n\nINTRODUCTION  \nFor decades, 5-Fluorouracil (5-FU) and its oral prodrugs (e.g., capecitabine, tegafur) have been cornerstone chemotherapy drugs for various cancers, including breast cancer and gastrointestinal cancer. Since the 1970s, 5-FU has maintained an important role in adjuvant breast cancer regimens, and the phase III CREATE-X/JBCRG-04 trial further demonstrated that capecitabine signiﬁcantly prolonged overall survival in patients with HER2-negative breast cancer [1] . These antimetabolites exert cytotoxicity by substituting dUMP with ﬂuorodeoxyuridine monophosphate (FdUMP), thereby inhibiting thymidylate synthase (TYMS), a critical enzyme in DNA synthesis [2, 3] . Despite targeting this essential replicative process, the efﬁcacy of 5-FU in breast cancer is limited, as evidenced by the GIM2 study showing the addition of ﬂuorouracil failed to optimize epirubicin, cyclophosphamide, and then paclitaxel (EC-P) based adjuvant chemotherapy for patients with high-risk early-stage disease [4, 5] . Therefore, improving the clinical utility of 5-FU remains a critical challenge.  \nThe cytotoxic effects of chemotherapeutic agents, including 5-ﬂuorouracil (5-FU), activate stress-responsive pathways in cancer cells. Although this activation can initiate cell death, it also  \nfacilitates cellular adaptation, leading to treatment refractory. ThemTORC1 pathway, a stress-responsive signaling hub, is a central driver of tumor growth and a known mechanism of resistance to diverse therapies [6–10] . In the BOLERO-1, -2, -3 trials, adding everolimus (an FDA-approved mTORC1 inhibitor","cbCaibuIctYUxJzU","https://ap.wps.com/l/cbCaibuIctYUxJzU","pdf",3514006,16,"English","# Introduction\n## Rationale for improving 5-FU utility in breast cancer\n## mTORC1 signaling and therapy resistance\n# Results\n## Everolimus increases HER2-negative breast cancer susceptibility to fluoropyrimidine","[{\"question\":\"How does everolimus sensitize HER2-negative breast cancer to 5-FU or capecitabine?\",\"answer\":\"Everolimus significantly enhances 5-FU efficacy and suppresses TYMS by promoting its proteasomal degradation, thereby sensitizing HER2-negative breast cancer to fluoropyrimidines.\"},{\"question\":\"What role do OGT and O-GlcNAcylation play in the proposed mechanism?\",\"answer\":\"Everolimus downregulates OGT, which reduces O-GlcNAcylation of TYMS. This promotes TYMS dissociation into monomers and ubiquitin-independent degradation.\"},{\"question\":\"Does restoring OGT affect TYMS degradation?\",\"answer\":\"Yes. Overexpression of OGT reverses TYMS degradation caused by everolimus, supporting OGT-dependent control of TYMS stability.\"}]","Everolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil | PDF",1790057550,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/008fd53470cfa1875725db21a8c441b2.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5ba7f2749fcd40a8500b5f35473bdce.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90aae3b60cba616d713fe55576ef1c2e.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df134ab3ecd98ecd5f16d62912621445.webp",980,1301]